Because the coronavirus responsible for the Covid-19 pandemic is new to humans, doctors lack vaccines to prevent it and proven medicines to treat it. Researchers and companies are scrambling to fill the void. In normal times, the process of approving new drugs is slow and painstaking. It can be accelerated in times of crisis such as these, but at the risk of doing more harm than good.
1. Are any Covid-19 treatments approved?
The U.S. Food and Drug Administration in late March controversiallyissued an Emergency Use Authorization providing for two malaria drugs, chloroquine and hydroxychloroquine, to be distributed and prescribed by doctors to Covid-19 patients. The move came after President Donald Trump repeatedly touted the drugs. Such authorizationsare permitted during a crisis when a product’s “known and potential benefits” outweigh its “known and potential risks.”
2. Why the controversy?
The FDA’s decision and Trump’s championing of the drugs have beencriticized byscientists as premature. In a small study in France, hydroxychloroquine showed promising results, but the trial’s methodology has been challenged, andin another small trial in China, the drug was no more effective than conventional care. And it carries significant side effects. Some people have been sickened, with reported deaths in the U.S. and France, after taking various versions to try to ward off or treat Covid-19. Plus panic-buying of hydroxychloroquine hascreated shortages of the drug for patients with malaria and the autoimmune disease lupus, for whom it is a proven therapy.
3. How do scientists prove a treatment is effective?
Even if a treatment shows promise in laboratory, animal or early human experiments, rigorous testing is needed to prove that it’s both safe and effective. That requires carefully structured and monitored tests known asclinical trials. Typically, these studies are designed to show that patients who get the drug do better than those who don’t, and that the results aren’t a product of chance. The trials try to subtract all the other influences and factors that might disguise the true effectiveness of the drug. For one thing, patients often recover from viral illness on their own, or improve because of supportive care such as rest and hydration. And some really sick patients might not respond to treatment no matter how effective it is. Treatments that don’t have approval from regulators such as the U.S. Food and Drug Administration should be viewed with extreme caution. The FDA and the U.S. Federal Trade Commissionhave warned multiple companies to stop sellingunproven treatments for coronavirus.
4. How long does it take to prove efficacy?
It depends. Drugs that are already approved against one infection and shown to be safe can be tested for effectiveness against another in a matter of months. Experimental drugs may take longer to test, as they have to go through initial studies to evaluate whether they are safe. Other factors that can slow the process include the supply of drug candidates and the availability of patients to test them in. The trials also have to be approved by ethics watchdogs and drug regulators. Accordingto a 2017 review, the median time for regulators to approve a new drug in 2015 was 333 days in the U.S., 422 days in Europe, and 639 days in China. China has sinceexpedited its process. When drugs are deemed to fill an immediate need, regulators can speed them through the approval process using anumber of paths.
5. What’s being tested against Covid-19?
More than 100 clinical trials have been launched in China tostudy everything from anti-flu drugs and antibody-containing plasma from recovered patients, to traditional Chinese herbal medicine. A smaller number have beenannounced in countries including the U.S., South Korea and Thailand. World Health Organization researchers have identified as the most promising agentremdesivir, an experimental antiviral made by Gilead Sciences Inc. originally as atreatment for Ebola. Inanimal studies, it produced encouraging results against related coronaviruses that cause severe acute respiratory syndrome (SARS) andMiddle East respiratory syndrome (MERS). Remdesivir trial results are expected from Chinain late April.Larger trials of chloroquine and hydroxychloroquine are starting. In astudy in China published March 18, AbbVie Inc.’s Kaletra, an HIV treatment combining two drugs, failed to improve the condition of coronavirus patients. Another small, preliminary trial of the flu medication favipiravir, or Avigan, made by Fujifilm Holdings Corp. producedmore promising results.
6. What about vaccines?
Moving atrecord speed, researchers began preliminary human testing of anexperimental Covid-19 vaccine in mid-March in the Seattle area. It was developed by the U.S. National Institute of Allergy and Infectious Diseases in collaboration with the biotechnology company Moderna Inc. Additional trials are expected as some of the world’s biggest companies areworking on vaccine projects. GlaxoSmithKlinehas teamed up with China-based Clover Biopharmaceuticals, whileSanofi andJohnson & Johnson are in separate collaborations with the U.S. government’sBiomedical Advanced Research and Development Authority. Widespread testing of experimental vaccines is important to reduce the possibility that they cause harm after being rolled out, as has been the case anumber of times in the past.
7. How soon might there be a vaccine?
Anthony Fauci, director of the U.S. National Institute of Allergy and Infectious Diseases, said that it would take about a year and a half to complete trials of experimental coronavirus vaccines, scale up production and make a licensed product widely available. There’s no guarantee trials will yield a successful vaccine, however. Moderna’s experimental product is a so-calledmessenger RNA vaccine, an unconventional approach that has yet to produce a vaccinelicensed for human use. SARS killed nearly 800 people in a 2002-2003 outbreak, and there still isn’t an approved vaccine. In a project that could deliver a vaccine sooner, researchers infour countries willtest a shot that’s already licensed to prevent tuberculosis to see if it will protect health workers against the coronavirus.
The Reference Shelf
- Related QuickTakes on what youneed to know about Covid-19, how thevirus spreads, whether towear a mask, whether the virus isseasonal, and how the pandemic isbeing fought.
- The U.S. National Institutes of Healthcompares the drug approval process in the U.S. to that in China.
- A commentary published by George Mason University’s Mercatus Center examinesChina’s reforms of its drug approval process.
— With assistance by Robert Langreth
Source: Read Full Article